Diagnostic Biochips, Inc is anchored in a biosensor platform technology that - by enabling direct and continuous monitoring of critical drugs and biomarkers - may redefine measurement in medicine. The Company has developed a proprietary sensor âfunctionalizationâ process and a suite of biosensors set to transform the medical monitoring process. The firm's paradigm-shifting sensors are a cost-effective method for the direct and continuous monitoring of medically important chemicals: a proprietary fast-response chemical sensing technology for use inside the body. Designed to make medical devices and implants "smart", the firm's capabilities provide information on biological activity: data that can be used in various applications: basic science research, neuromodulation, continuous diagnostics, and pharmacodynamic analysis. The medical practitioner orders blood and urine tests, biopsies and other tissue samples. These procedures yield biochemical concentrations at the specific with almost no other information available re. how concentrations vary with time. In the case of stroke or heart attack, for example, it has been shown that the presence of certain biomarkers indicates a high probability of onset.. However, with no practical means to monitor an at-risk patient for the sudden appearance of these indicators is less than useful. Initially focusing primarily on applying its technology in the area of pre-clinical drug development, Diagnostic Biochips sells its first product -- the Neuro Mapping Microsensor (NMM) -- through distributor Cambridge NeuroTech.This silicon probe product is used by neuroscientists to study how the brain processes information. Drug discovery groups at pharmaceutical companies and contract research organizations are using the NMM sensors to study the efficacy of novel drug candidates for a variety of neurological diseas
